Objective: Head and neck cancers (HNC) are known for their repopulation ability driven by cancer stem cells (CSCs). While a small fraction of CSCs proliferates, there are quiescent CSCs that are long-lived and reside outside the cell cycle. Recruitment of quiescent CSCs into the cycle occurs as a response to cell loss and their proliferation may lead to treatment failure. Therefore, CSCs require a more targeted approach to be destroyed. An agent that sensitizes CSC response to treatment is all-transretinoic acid (ATRA). The aim of this work is to assess the impact of ATRA combined with radiotherapy on HNC and to analyse the interplay between these agents and cell recruitment. Yet, when CSCs are being recruited, the dose enhancement factor is significantly greater (DEF = 1.89). Radiation-induced cell arrest and CSC sensitization by ATRA significantly decreases the dose required for CSC eradication in the cycling population.
| INTRODUCTION

| Treatment-related challenges in head and neck cancer
In head and neck cancer (HNC) accelerated tumour repopulation is a major cause of treatment failure, reason why prolonged radiotherapy schedules should be avoided. This is valid particularly for tumours comprising of large cancer stem cell (CSC) compartment that can fast regrow the tumour as a response to treatment-induced cell kill.
To overcome repopulation and tumour hypoxia, which are the two main culprits for poor treatment outcome, the conventional radiotherapy schedule (2 Gy/fraction, 5 days a week, over 7 weeks) has been altered. Altered fractionation schedules that were successfully trialled are accelerated radiotherapy and hyperfractionated radiotherapy.
Accelerated radiotherapy shortens the overall treatment time, while hyperfractionated radiotherapy is designed to overcome repopulation and promote reoxygenation in between fractions. Based on a metaanalysis of head and neck cancer trials, hyperfractionated radiotherapy proved to be superior in tumour control to accelerated radiotherapy. 1 Within hyperfractionated radiotherapy 2 or more small doses (<2 Gy) of radiation are administered week-daily, which results in a larger overall delivered dose compared to conventional radiotherapy. In another experiment, Tang et al 5 has indicated that the CSC proportion in various HNC cell lines ranged between 1.7% and 13.5%.
These variations demand more quantitative and qualitative studies to explain the differences.
| Properties of cancer stem cells and their importance for the current study
Cancer stem cells have several specific properties that make them immortal and resistant to therapy. Table 1 presents the most common properties, based on experimental evidence. Resistance to treatment is multifactorial and includes (i) the ability of CSC to efficiently repair damaged DNA, (ii) the capacity to divide symmetrically (ie, symmetric self-renewal of CSC in mitosis resulting in two CSCs), which contributes to tumour repopulation, (iii) the preference of CSCs to reside in specific microenvironmental niches in order to conserve their status and (iv) the ability of the quiescent CSCs to be recruited into the cell cycle.
It was shown that activation of Notch signalling that regulates cell fate, can recruit quiescent stem cells into the cell cycle. 6 Fractionated radiotherapy was demonstrated to promote cell recruitment, increasing the cycling CSC population.
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All the above properties of CSCs have a critical role in tumour response to therapy and therefore should be investigated and addressed accordingly. The present study tackles several of these properties in order to establish means of treatment optimization in HNC.
| Targeted therapies for cancer stem cells
Although altered fractionation radiotherapy is a powerful tool in the management of head and neck cancer, CSCs require targeted therapy in order to be destroyed. Several CSC-targeting pathways have been investigated so far and several others are under investigation.
The focus of this work is on all-trans-retinoic acid (ATRA) which is an agent that exhibits cell cycle effects by sensitizing CSC response to treatment. ATRA is a member of the retinoid family and has a potent effect on cell growth, differentiation and apoptosis. [15] [16] [17] Retinoids have the ability to influence multiple signalling pathways that are involved in stem cell preservation. 15 As demonstrated by in vitro and in vivo preclinical studies, ATRA exhibits powerful effects on CSCs by inducing cell cycle arrest due to the complexity of DNA damage and also apoptosis. 16, 17 The same studies have proven the ATRA-induced differentiation, associated with downregulation of the Wnt pathway, which is a central mechanism for controlling malignant transformation. According to Bertrand et al, ATRA combined with radiotherapy resulted in a decrease in the surviving fraction among the head and neck cancer cell population. 17 Furthermore, Zhang et al have shown that ATRA can efficiently inhibit telomerase activity in oral squamous cell carcinoma cell lines that leads to the induction of growth arrest in these tumours. 18 
| The aim and design of the current work
The current work is based on the above described CSC properties that have been proven to influence response to treatment, particularly in head and neck carcinoma patients. The aim of this study is multifold:
1. to investigate using modelling tools the effect of cell recruitment on treatment outcome, as a function of the recruited cell type (ie, CSC or differentiated);
2. to implement the mechanisms of ATRA combined with radiotherapy and to evaluate treatment response for the tumour as a whole;
3. to assess the interplay between the combined effect of ATRA/radiotherapy and cell recruitment. with the scientific literature that shows that over 80% of cells reside outside the cell cycle, in the quiescent phase. 21 The virtual tumour is modelled to be moderately hypoxic, with an average pO 2 value of 6 mm Hg. This consideration is due to the fact that head and neck cancers are known to be generally hypoxic, a property that increases radioresistance.
| METHODS
ATRA:
The effects of ATRA (differentiation, cell arrest and apoptosis)
are modelled based on scientific literature data. In a previous work, Labelling index 4.7% 8% (1.2-30) 23 Cell division rate (24 h) 1.3% Model-derived parameters based on the above tumour growth parameters
Pre-treatment probability of CSC symmetrical division
1.9%
Pre-treatment percentage of CSCs 5.9%
Cell phenotype ratio CSC:D:Q 5.9:7.9:86.2
Radiotherapy-related parameters (linear quadratic model parameters)
Average surviving fraction after 2 Gy (SF 2 ) 54% 54% 
| RESULTS
| Conventional vs hyperfractionated radiotherapy in a moderately hypoxic tumour
As discussed in the Introduction, the results of phased III randomized clinical trials have shown that hyperfractionated radiotherapy is superior to the conventionally fractionated radiotherapy regimen in head and neck cancers. The simulation on the virtual head and neck tumour of the two treatment regimens using the same clinical dosage and fractionation schedules as employed in the trials is represented in Figure 2 and the results are in accordance with the clinical findings. The trial 1 showed a superior outcome in terms of locoregional control in patients undergoing hyperfractionated as compared to conventional radiotherapy. This outcome is translated in the model
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by the more efficient and timely cell kill offered by hyperfractionation compared to the much longer treatment time and dose required from conventional therapy to achieve the same effect. Given that the mentioned randomized trials did not stratify their patients based on hypoxia, the current model considered the 'average' patient with a moderately hypoxic tumour.
In the paragraphs below we are presenting the effects of (i) recruitment as a single mechanism, (ii) ATRA combined with hyperfractionated radiotherapy and (iii) ATRA combined with hyperfractionated radiotherapy when considering the recruitment mechanism.
| The model of cell recruitment and radiotherapy outcome
The behaviour and survival of three cell categories is studied: can-
cer stem cells (CSC), differentiated cells (D) and quiescent cells (Q).
The modelled cell recruitment process considers either CSC or D cell recruitment.
The highly potent effect of CSCs on treatment outcome is well illustrated in Figure 3 and is in accordance with the properties described in Table 1 , particularly repopulation and radioresistance.
The effect of proliferation and symmetrical division displayed by
CSCs is intensified by the surplus CSC population brought into the cell cycle by the recruitment mechanism, leading to a significant increase in the required dose for tumour kill.
This radiation-triggered cellular recruitment is a natural response of the tumour to outlive treatment through activation of its DNA repair capacity, symmetrical division and accelerated proliferation.
As an interesting result, recruitment of D cells leads to a lower
overall dose required for tumour kill as compared to no recruitment.
Once recruited, cells leave the safety net of the G 0 phase, so subsequent doses of radiation find them in a more radiosensitive part of the cell cycle. This sensitization to radiation represents the silver lining of the recruitment mechanism.
| The effect of ATRA/radiotherapy on CSC population and on the tumour as a whole without recruitment
We have shown in a previous study that ATRA exhibits powerful effects on cancer stem cells. 25 In the mentioned study, the in silico model indicated that the cellular effects displayed by ATRA combined with radiotherapy lead to a more powerful outcome than radiotherapy (Figure 5) , whereas radiotherapy as a single agent was not able to overcome repopulation due to recruitment, thus the tumour could not be killed within the clinically set schedule (Figure 3) .
A comparative analysis of Figures 3, 4 and 5 shows that recruitment on its own forces the CSC population into untreatable territory (Figure 3 ). Without recruitment, ATRA has a "magic bullet" effect on the CSCs (Figure 4 ), while Figure 5 shows the combined effect of the two opposing forces (recruitment and ATRA), illustrating that ATRA provides a valuable service bringing the CSC population under the treatment threshold of altered fractionated radiotherapy.
| Quantitative evaluation of ATRA effects: dose enhancement factor
In order to undertake a quantitative assessment of ATRA effects on tumour control when combined with radiotherapy, the Dose Enhancement Factor (DEF) is determined as the ratio between the dose with radiotherapy and the dose with radiotherapy + ATRA, for the same biological effect (tumour control). Table 3 The aim of the current in silico model is to assess the impact of a CSC-targeting agent (ATRA) combined with radiotherapy in the treatment of HNC, and to evaluate the effect of the combined modality treatment on the tumour population as a whole. We show that while ATRA has a powerful effect on CSCs, the overall behaviour of the tumour is dictated by the large percentage of quiescent cells. The focus therefore is on the quiescent population that can be triggered into the cell cycle by treatment.
Experimental studies provide evidence for cell recruitment, which is the process of re-entry of quiescent cells into the mitotic cycle triggered by cell loss. Nevertheless, the literature lacks quantitative data concerning the recruited population as well as the quality of recruited cells (ie, cell type). In view of the above, it is critical for future experimental work to quantify recruitment in head and neck cancer in order to design treatments that account for such an effect.
Based on the model results, the following challenging questions need practical attention:
• Should quiescent cells be targeted for eradication in the G 0 phase?
• Should quiescent cells be triggered into the cell cycle and targeted there?
• Should quiescent cells be left in their current state?
As shown by our modelling work, the answers to the above ques- Considering that head and neck cancers are typically poorly oxygenated, the simulated tumour is a moderately hypoxic HNC with an average pO 2 (partial oxygen pressure) value of 6 mm Hg. This fact influences overall radioresistance, as hypoxic cells are known to have a more efficient DNA repair capability. Thus, if a tumour is less hypoxic than the one modelled above (pO 2 > 6 mm Hg), the overall response to radiotherapy is likely to be superior, whereas in a more hypoxic tumour (pO 2 < 6 mm Hg) the outcome is probably worse.
Given the fact that the literature focuses on the effect of ATRA on cancer stem cells only, no interaction between this agent and nonstem cancer cells has been modelled in this work.
As a final conclusion, ATRA exhibits a powerful effect on CSCs when combined with radiotherapy. However, as shown by the model, the more radioresistant quiescent cell population should not be ignored, as it can be a potential threat to treatment outcome when cells are recruited into the cell cycle.
